# vTv Therapeutics Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/vTv Therapeutics Inc.). ## Overview vTv Therapeutics Inc. is a U.S.-based biopharmaceutical company organized as a holding company with operations conducted through vTv Therapeutics LLC. The company focuses on discovering and developing drug candidates, with cadisegliatin as its principal program in diabetes and additional assets licensed from third parties and collaborators. ## Products & services • Cadisegliatin, a glucokinase activator program • Preclinical and clinical-stage drug development • Licensed compound development and commercialization rights • Collaboration and milestone-based research programs • Out-licensing of intellectual property and drug candidates - **Clinical-stage drug candidates** (60%) — Drug programs in human clinical development, including cadisegliatin for diabetes. - **Licensed preclinical assets** (25%) — Compounds and programs licensed from partners for discovery and development. - **Collaboration and milestone revenue** (15%) — Up-front fees, development milestones, and research fees from partners. - Cadisegliatin, a glucokinase activator program - Preclinical and clinical-stage drug development - Licensed compound development and commercialization rights - Collaboration and milestone-based research programs - Out-licensing of intellectual property and drug candidates ## Customers vTv Therapeutics does not sell commercial drugs today; its economic counterparties are pharmaceutical partners, licensees, and collaborators that fund development through licenses, milestones, and research agreements. In a future commercialization scenario, its end customers would be patients and healthcare providers in diabetes and related metabolic disease markets. The company’s current business model is therefore partner-driven, with value created through clinical progress and intellectual property rights rather than product sales. - **Pharmaceutical collaboration partners** (primary) — Companies or institutions that license programs and pay milestones, up-front fees, or research support. - **Clinical development partners** (primary) — Organizations involved in running or supporting trials for cadisegliatin and related programs. - **Future diabetes patients** (secondary) — Patients who would use an approved therapy such as cadisegliatin if development succeeds. - **Healthcare providers and payors** (secondary) — Physicians and reimbursement decision-makers who would influence adoption of any approved product. - Pharma partners that license compounds and fund development - Collaborators paying up-front fees and milestone payments - Potential future prescribers and patients in diabetes care - Regulatory and clinical stakeholders enabling trial progression - Commercial partners that could market approved products ## Geography vTv Therapeutics is headquartered in the United States, but its development model is international because its programs and partnerships can span multiple regions. The company has disclosed planned clinical activity in the Middle East for type 2 diabetes and expects future registrational studies for type 1 diabetes to be international as well. As a development-stage biopharma company, geography matters mainly through trial execution, regulatory pathways, and partner reach rather than manufacturing footprint. - **United States** (100%) — Corporate headquarters and primary operating base; no country revenue disclosure provided - Headquartered in the United States - Clinical development can extend into international trial sites - Middle East trial planned with partner G42 - Future registrational studies expected to be multinational - No owned manufacturing footprint; relies on third parties ## Strategy The company’s strategy centers on advancing cadisegliatin through clinical development and securing the regulatory evidence needed for later-stage studies and potential approval. It also uses partnerships and licensing to fund development, broaden geographic reach, and preserve optionality around future commercialization. Because it has no approved products, execution depends on trial design, partner alignment, and maintaining intellectual property rights. - **Advance cadisegliatin into registrational studies** (medium-term) — Clinical proof is the main driver of value for a development-stage biopharma company. - **Use collaborations to finance development** (short-term) — Milestones, up-front fees, and research payments support operations before product sales exist. - **Expand international development footprint** (medium-term) — Broader geography can support enrollment, regulatory strategy, and future market access. - Advance cadisegliatin through registrational development - Use partnerships to fund and de-risk development - Expand trial footprint beyond the U.S. - Preserve value through licensing and IP control - Prepare for future commercialization or partnering ## Risks The company faces the core risks of development-stage pharmaceuticals: clinical failure, regulatory delays, safety findings, and uncertainty over eventual approval. It also depends on third-party manufacturers and collaborators, so supply disruption, partner termination, or weak financing access could slow or stop development. If approved, commercialization would still depend on reimbursement, market acceptance, and competition from better or faster-moving diabetes therapies. - **Clinical trial delay or failure** [critical] — Development-stage assets can lose value if enrollment, endpoints, or safety results disappoint. - **Regulatory approval risk** [critical] — The company has no approved products and must satisfy FDA and other regulators. - **Third-party manufacturing dependence** [high] — The company does not own manufacturing facilities and relies on external suppliers. - **Partner and funding dependence** [high] — Milestone and collaboration revenue depends on counterparties and contract continuity. - **Commercialization and reimbursement risk** [medium] — Even if approved, uptake depends on pricing, payor coverage, and competition. - Clinical trials may be delayed, fail, or be placed on hold - Regulatory approval is uncertain and can take years - Third-party manufacturing creates supply and quality risk - Partner terminations can reduce funding and program value - Commercial adoption and reimbursement are uncertain if approved ## Accounting Revenue is highly judgmental because it comes mainly from collaboration fees, up-front proceeds, and milestone payments rather than product sales. The company also has meaningful quarterly volatility because revenue recognition depends on contract events and development milestones, while R&D spending tracks trial timing and program activity. As a holding company with a VIE subsidiary, consolidation judgments, share-based compensation, and potential impairment or tax estimates can also affect reported results. - **Revenue recognition for collaboration and milestone payments** — Can create large quarter-to-quarter swings in reported revenue - **Research and development expense timing** — Affects operating loss trends and comparability across periods - **Variable-interest entity consolidation** — Determines which assets, liabilities, and results appear in the financial statements - **Share-based compensation** — Can materially affect operating expenses and equity balances - Milestone and collaboration revenue depends on contract achievement - No drug sales yet, so revenue timing can be lumpy - R&D expense varies with trial design and development timing - VIE consolidation affects how subsidiary results are reported - Share-based compensation and tax estimates can move earnings --- *Last updated: 2026-04-29T05:12:42.267824+00:00*